key: cord-0310891-tpwbb0bk authors: Rhodes, Johanna; Abdolrasouli, Alireza; Dunne, Katie; Sewell, Thomas R.; Zhang, Yuyi; Ballard, Eloise; Brackin, Amelie P.; van Rhijn, Norman; Tsitsopoulou, Alexandra; Posso, Raquel B.; Chotirmall, Sanjay H; McElvaney, Noel G; Murphy, Philip G; Talento, Alida Fe; Renwick, Julie; Dyer, Paul S.; Szekely, Adrien; Bromley, Michael J.; Johnson, Elizabeth M.; White, P. Lewis; Warris, Adilia; Barton, Richard C.; Schelenz, Silke; Rogers, Thomas R.; Armstrong-James, Darius; Fisher, Matthew C. title: Tracing patterns of evolution and acquisition of drug resistant Aspergillus fumigatus infection from the environment using population genomics date: 2021-04-08 journal: bioRxiv DOI: 10.1101/2021.04.07.438821 sha: 5d846626f61b2b88433d4e49eadf18f347834b8d doc_id: 310891 cord_uid: tpwbb0bk Infections caused by opportunistic fungal pathogens are increasingly resistant to first-line azole antifungal drugs. However, despite its clinical importance, little is known about the extent to which susceptible patients acquire infection from drug resistant genotypes in the environment. Here, we present a population genomic analysis of the mould Aspergillus fumigatus from across the United Kingdom and Republic of Ireland. First, we show occurrences where azole resistant isolates of near identical genotypes were obtained from both environmental and clinical sources, indicating with high confidence the infection of patients with resistant isolates transmitted from the environment. Second, we find that the fungus is structured into two clades (‘A’ and ‘B’) with little interclade recombination and the majority of environmental azole resistance genetically clustered inside Clade A. Genome-scans show the impact of selective sweeps across multiple regions of the genome. These signatures of positive selection are seen in regions containing canonical genes encoding fungicide resistance in the ergosterol biosynthetic pathway, whilst other regions under selection have no defined function. Phenotyping identified genes in these regions that could act as modifiers of resistance showing the utility of reverse genetic approaches to dissect the complex genomic architecture of fungal drug resistance. Understanding the environmental drivers and genetic basis of evolving fungal drug resistance needs urgent attention, especially in light of increasing numbers of patients with severe viral respiratory tract infections who are susceptible to opportunistic fungal superinfections. Fungal infections are often neglected, yet affect more than a billion people worldwide; 65 mortality caused by fungal diseases matches that found for malaria or tuberculosis 1 Aspergillus fumigatus is a globally ubiquitous environmental mould, which may 67 opportunistically cause fungal lung disease. Although healthy human lungs clear inhaled 68 inocula, invasive aspergillosis (IA) can occur in the ever increasing at-risk population with 69 severe neutropenia, haematopoietic stem cell or solid organ transplants, those receiving 70 immunosuppressive therapy (e.g. autoimmune diseases), and is emerging as an important 71 pathogen as an influenza-and COVID-19 associated infection 22,3 . Patients who suffer chronic 72 infection by A. fumigatus include those with pulmonary conditions such as cystic fibrosis 73 (CF) and severe asthma. CF patients are particularly at high risk, with 30% developing 74 Aspergillus-related bronchitis and 18% developing allergic bronchopulmonary aspergillosis 75 (ABPA) in adulthood 4 . Collectively, millions of individuals suffer from aspergillosis 76 worldwide, with over 2.25 million occurring in the European Union alone 5 testifying to the 77 broad scale nature of the problem. 78 79 Triazole antifungal drugs are usually effective against A. fumigatus and comprise firstline 80 therapy for prophylaxis and treatment of IA 6 . However, emerging resistance to azoles has 81 been reported 7 worldwide for both environmental and clinical isolates 8, 9 . Triazole antifungal 82 drug resistance has serious clinical implications, with retrospective studies of patients 83 infected with IA-associated azole-resistant A. fumigatus showing a 25% increase in mortality 84 at day 90 when compared with patients with wild-type-infections 10 . While in vivo 85 emergence of resistance during extended azole therapy is well documented 11,12 , ex vivo 86 evolution of resistance in the environment as a result of exposure to sterol 14-87 demethylation inhibitor (DMI) fungicides has also been postulated 13, 14 . These agricultural 88 chemicals have been increasingly and widely used since their development in the 1970's and 89 affect pan-fungal sterol and related membrane biosynthesis by targeting the enzyme 14α-90 sterol demethylase. Azole resistance in A. fumigatus is thought to occur via the unintended 91 selection by DMIs for isolates with reduced sensitivity due to polymorphisms in the cyp51A 92 gene that encodes this membrane-building enzyme. Broadly, azole-resistance in A. 93 fumigatus occurring in the environment is characterised by signature mechanisms involving 94 expression-upregulating tandem repeats (TR) in the promoter region of cyp51A 95 accompanied by point mutations within this gene which decrease the affinity of azoles for 96 the target protein; the most commonly occurring alleles are known as TR34/L98H and 97 TR46/Y121F/T289A and are associated with high level itraconazole and voriconazole 98 resistance respectively both inside and outside of the clinic 15-17 . The spatially widespread 99 occurrence of these canonical alleles alongside increasing reports of more complex cyp51A 100 resistance-associated polymorphisms 18-20 underpin the hypothesis that the broad 101 application of agricultural azole fungicides is driving natural selection, amplification and 102 ultimately acquisition of azole-resistant airborne A. fumigatus conidia by susceptible 103 patients 21 . Furthermore, the potential for global spread of these resistance mechanisms 104 through floriculture products, especially plant bulbs, has been demonstrated 22 , while the 105 global dispersal of conidia on air-currents is impossible to contain. There is a need to explore the potential link between the increasing clinical incidence of 108 azole-resistant aspergillosis and the increasingly broad range of azole resistant genotypes 109 that are being reported in the environment 23 using modern genomic epidemiological 110 methods. The rate at which environmental resistance develops will be determined by the 111 strength of natural selection by azole fungicides acting on beneficial mutations, a process 112 that is further influenced by recombination, gene flow, and dispersal with the latter likely 113 being substantial for A. fumigatus given its ubiquitous presence in nature and airborne 114 buoyancy of conidia. Whilst azole-resistant alleles can potentially segregate into diverse 115 genetic backgrounds through sex 24 , the majority of A. fumigatus reproduction in the 116 environment is thought to occur asexually 26 producing clones with high genetic similarity. 117 Therefore, a priori expectations are that the genomes of azole-resistant A. fumigatus will 118 exhibit the genetic signatures of linkage, selective sweeps, and divergence of selected loci 119 from the wild-type population that is predicated on the amount of population-wide 120 recombination. Ultimately, clonality will cause high genetic similarity between clinical 121 isolates and their near-contemporaneous environmental progenitors, discovery of which 122 constitutes epidemiological evidence for the acquisition of azole resistant aspergillosis. 123 Evidence for these expectations comes from a recent global study by our laboratory 124 demonstrating the non-random distribution of azole resistance in A. fumigatus multilocus 125 microsatellite genotypes worldwide, compatible with selective sweeps caused by genetic 126 hitchhiking alongside azole-resistance polymorphisms 27 . 127 128 Here, we used whole genome sequencing to interrogate the spatial and molecular 129 epidemiology and population genomics of a broad panel of A. fumigatus isolates collected 130 from medical centres and environmental sites across England, Wales, Scotland and the 131 Republic of Ireland. The aim of our study was to understand the genetic architecture of A. 132 fumigatus populations in this region in order to prove, or disprove, the proposed link 133 between azole-resistance found in the environment and patients. Methods 136 137 Fungal isolates 138 139 A total of 218 isolates were included in this study. 153 clinical A. fumigatus isolates from five 140 participating centres were included. Patients either had respiratory colonisation with A. 141 fumigatus or were suffering from different manifestations of aspergillosis and had the 142 following underlying disorders ( We analysed a coancestry matrix based on whole-genome SNP data to assign individuals to 219 populations via model-based clustering using fineStructure 43 v2.0.7. FineStructure uses 220 chromosome painting to identify important haplotypes and describe shared ancestry within 221 a recombining population. These analyses were performed using a pan-clade genome-wide 222 SNP matrix to infer recombination, population structure and assignment, and ancestral 223 relationships of all lineages. ChromoPainter reduced the SNP matrix to a pairwise similarity 224 matrix under a linked model, using information on linkage decay and reducing the within-225 population variance of the coancestry matrix relative to the between-population variance. 226 227 Sliding-window population genetic statistics (Tajima's D, nucleotide diversity  and FST) were 228 calculated for non-overlapping windows of 10 kb using vcftools 44 v0.1.13, with resulting 229 graphics produced in R v3.5.3 using ggplot2. The index of association and rBarD are commonly used to estimate linkage disequilibrium. 232 These two statistics were calculated using Poppr v2.8.5 45 in R v3.5.3 using 999 resamplings 233 of the data under the null hypothesis of recombination. Identifying loci associated with itraconazole resistance using genome-wide association 236 237 Loci associated with itraconazole resistance were identified using treeWAS 46 , a method that 238 was recently developed to address challenges specific to microbial genome-wide association 239 studies (GWAS). TreeWAS uses phylogenetic information to correct for the microbial 240 population structure; we therefore used the phylogeny presented in this study along with a 241 nucleotide alignment for all 218 isolates. found to contain the MAT1-1 mating type idiomorph (Table S2) . Mating type was reported 277 for all isolates; a chi-square test showed a significant bias towards the MAT1-2 idiomorph (P 278 < 4.82983e -05 ), primarily seen in the environmental (P < 1.00183e -05 ), and to a lesser extent 279 the clinical (P < 0.04396), populations (Table S2 ). The genomic dataset can be browsed as a 280 Microreact project 52 at https://microreact.org/project/6KR8996ywtVRV5wm233YhP 281 ( Figure S1 ). 282 283 EUCAST clinical antifungal breakpoints (www.eucast.org) were used to determine the 284 susceptibility of isolates, with the exception of Irish isolates, where susceptibility was 285 determined using CLSI methodology as described by Dunne et al. 22 . As clinical breakpoints 286 from EUCAST and CLSI were broadly similar for A. fumigatus they were pooled in our 287 analyses. Other studies have also found CLSI and EUCAST MICs to be similar 53,54 . We report 288 (Table S3) (n = 44) to posaconazole (≥0.5 mg/L). We found 26 isolates (12%) that exceeded MIC 293 breakpoints to two or more azole drugs from both clinical (n = 23) and environmental (n = 3) 294 sources. Seventeen isolates were not tested for antifungal susceptibility via EUCAST or CLSI; 295 of these, 14 contained drug resistance polymorphisms (TR34/L98H or TR46/Y121F/T289A) 296 and three contained no known drug resistance polymorphism. Thirteen isolates reported 297 raised MICs but displayed no known drug resistance polymorphisms. These isolates are 298 summarised in Table 3 . Among the 218 genomes, 329,261 sites along the 30 Mb genome were found to be 301 polymorphic (~1.1%), similar to that seen in our previous study using a small number of 302 isolates recovered across a global-scale 21 . Pairwise identities show that, on average, each 303 isolate of A. fumigatus in this dataset differs from all others by 11,828 single nucleotide 304 polymorphisms (SNPs) testifying to the highly-discriminatory nature of this genotyping 305 method. Tandem repeats and SNPs causing non-synonymous amino acid substitutions in 306 cyp51A encoding 14-α lanesterol demethylase, the target of triazole antifungals, are 307 summarised in Table S1 for all isolates where present. Identified polymorphisms were 308 compared to known polymorphisms conferring resistance using the MARDy database 55 . The 309 majority of clinical isolates (n = 91 (59.5%)) exhibited wildtype cyp51A, whilst TR34/L98H was 310 predominant in environmental (n = 41 (63.1%)) isolates. The TR34/L98H polymorphism was 311 the drug resistance allele found to occur with highest frequency in both clinical (n = 44 312 (28.8%)) and environmental populations (n = 41 (63.1%)) respectively; a second published 313 polymorphism, TR46/Y121F/T289A, was only found in the environmental population (n = 7). 314 Other cyp51A nonsynonymous polymorphisms known to be associated with azole resistance 315 were also present within this dataset including: P216L (n = 2), G54W (n = 9), G54E (n = 1), 316 G54R (n = 3) ( Figure 1 ). These genotypes and their relative frequencies are presented in 317 Table 2 . The TR46/Y121F/T289A genotype and a single TR34 only (without the L98H 318 substitution) were only recovered from environmental isolates. Alongside known resistance 319 polymorphisms we found a novel cyp51A genotype associated with azole-resistance within 320 the UK, the TR-associated polymorphism, TR34/L98H/T289A/I364V/G448S, which was 321 detected in four isolates (C155-C158) collected in 2016 from a sputum sample of one 322 patient with necrotising aspergillosis; these four isolates were found to contain this novel 323 polymorphism, manifesting a multi-azole resistant phenotype (Table S2) , demonstrated by 324 high MIC values for itraconazole, voriconazole (both ≥ 16 mg/L) and posaconazole (4 mg/L). 325 These isolates (with the exception of C155) were phenotypically distinct from classical A. 326 fumigatus displaying slower growth rates with less pigmentation and fewer or no conidia 327 compared to classical A. fumigatus, yet were confirmed to be A. fumigatus by mass 328 spectrometry and the subsequent genome sequencing. All four isolates were MAT1-2, and 329 were only separated by 145 SNPs on average, compared to over 11,000 SNPs that on 330 average separate any pair of isolates in this dataset. This allele was only recovered in-331 patient and was not found in the environment ( Whole genome SNP data were transformed using Principal Component Analysis (PCA) to 364 identify the optimal number of clusters (k) corresponding to the lowest Bayesian 365 Information Criterion (BIC). Here, we identified three clusters, containing a mix of 366 environmental and clinical isolates in each, which broadly corresponded to the previous 367 phylogeny ( Figure S3 ): the first cluster corresponded to a subset of Clade A containing a 368 broad selection of cyp51A polymorphisms (henceforth referred to as Cluster 1); the second 369 cluster corresponded to Clade B (Cluster 2), and the third cluster overlapped with isolates 370 within Clade A containing TR34/L98H only (henceforth referred to as Cluster 3). These 371 genetic clusters displayed no geographical or temporal clustering ( Figure S3 ). Discriminant 372 Principal Component Analysis (DAPC) was used to examine the extent of divergence 373 between genetic groups, whilst minimising variation within groups; this analysis confirmed 374 the three genetically distinct clusters (Figure 2b ). These three clusters were also confirmed 375 using STRUCTURE and k = 3 (Figure 2c ). Minimum inhibitory concentrations (MICs) for the three test azole antifungal drugs, as well 378 as the occurrence of polymorphisms associated with the cyp51A gene, were significantly 379 higher in Clade A overall than in Clade B ( 2 test p-value = 3.27308e -14 , df = 1). For tandem-380 repeat associated polymorphisms, 100% of the TR34 and 71% (n = 5) of the TR46-associated 381 alleles occurred within Clade A, strikingly showing a complete absence of the commonly 382 occurring TR34 genotype from Clade B). We found that less than a quarter (23%; n = 75,317 SNPs) of the total A. fumigatus diversity 385 seen in the whole dataset occurs within Clade A, despite this clade comprising 56% of the 386 total isolates sampled. Of this nucleotide diversity within Clade A, no SNPs were uniquely 387 associated with TR34/L98H or TR46 polymorphisms (the latter are distributed across Clades A 388 and B). These data mirror those found by STRAf microsatellite analysis, illustrating that 389 isolates harbouring drug resistance polymorphisms display reduced genetic diversity and are 390 genetically depauperate in comparison to randomly-selected wild-type isolates 27 . We estimated the index of association (IA) and the modified statistic rBarD 45 in order to 393 determine whether a signal of recombination is present within Clusters 1, 2 and 3. We 394 assumed the null hypothesis of no linkage disequilibrium, meaning therefore that no 395 recombination would not be rejected if the resulting values of both statistics were not 396 significantly different from the distribution of values obtained from 999 samplings. For all 397 three clusters, the null hypothesis could not be rejected, implying no significant linkage 398 among the loci, and therefore that all three clusters are recombining with each other. In 399 order to further explore recombination within A. fumigatus in the context of its population 400 structure, we implemented a chromosome painting approach using fineStructure 43 , which 401 identified shared genomic regions between individuals and populations. The linked 402 coancestry model found the highest level of sharing within clades ( Figure 3 ). Individual 403 isolates C4, C54 and C178 within Clade B displayed evidence for strong haplotype sharing. 404 These three isolates are all MAT1-2 idiomorph. C4 was isolated from a soil sample in South 405 Wales, C178 in a London hospital (a clinical isolate) and C54 is a clinical isolate from Dublin, 406 Republic of Ireland (Supplementary Table 1 We next performed further population-level genome-wide analyses in order to investigate 413 whether local regions of the genome were differentially associated with respect to clade 414 and resistance phenotype. We measured signatures of genome-wide population 415 differentiation via the fixation index (FST) analysis of non-overlapping 10 kb windows by 416 comparing isolates within Clade A against those isolates from Clade B (Figure 4b ). The 417 average FST value was 0.1312 (range: from 0 to 0.944035; standard deviation 0.0823); 418 average FST values and ranges for each chromosome are detailed in Table S3 . Regions of 419 extremely variable FST values were observed in Chromosome I (range 0 to 0.9440). In 420 particular a region of 590 kbp on the right arm of this chromosome displayed an average FST 421 value of 0.2273, but with a range in FST values from 0 to 0.944035, suggesting near panmixis 422 in some parts of this region between Clades A and B. Across this region 184 genes are found 423 (gene ID Afu1g15860 to Afu1g17640 (Supplementary Data 4)). Of these genes, 9 contained 424 SNPs which were found to be significantly associated with itraconazole resistance using 425 treeWAS. Also within this region in Chromosome I, three extremely high outlier F ST values 426 were observed where the average FST value was 0.9321 (range: 0.9238-0.9440) with the 427 spanned regions containing 9 genes (Table S4) . Regions of higher than average FST (around 0.5) were also observed in Chromosomes IV and 430 7 ( Figure 4b ). The average FST value for the cyp51A region, found in Chromosome IV, was 431 0.1193, slightly less than the average FST value for the whole dataset (0.1312). In order to investigate whether a signature of selection was observed across the genome of 434 UK A. fumigatus, we used Tajima In order to determine the extent that variation in Tajima's D and FST owe to intra-clade 445 population substructure, we subset the dataset into the three clusters that were defined by 446 PCA, DAPC and STRUCTURE. As before, we used non-overlapping 10 kb sliding windows to 447 estimate the two statistics. Three-way FST ( Figure S4 ) between the three clusters (Cluster 1 448 and Cluster 3, and Clade B (Cluster 2)) shows regions in Chromosome I that are approaching 449 FST of 1, showing that these highly-diverged alleles are present across Clade A. There were Clade A is largely owed to population substructure. Identifying loci significantly associated with itraconazole resistance 460 461 treeWAS is a microbe-specific approach that utilises a phylogeny-aware approach to 462 performing genome-wide association whilst being robust to the confounding effects of 463 clonality and genetic structure. We applied treeWAS to all sequenced isolates with reported 464 itraconazole MICs and a binary phenotype (205 out of 218 isolates). The binary phenotype 465 was categorised according to the itraconazole MIC defining susceptibility as MIC < 2 mg/L 466 and resistant as MIC  2 mg/L. A phylogeny for these isolates was reconstructed as 467 previously described with 281,874 SNPs common to one or more isolates with reported 468 itraconazole MIC. Analysis of this dataset led to the identification of 2,179 significant loci using the subsequent 471 test; this test has been previously defined by Collin & Didelot 46 as most effective at 472 detecting subtle patterns of association. Sixty-four percent of significant loci (n = 1,391) 473 were found to be intergenic. The three most significant loci (p < 2.03 e-06 ) were all located on 474 Chromosome IV: one was intergenic (position 1779747), one was a non-synonymous SNP 475 (S237F) in Afu4g07010 (position 1816171) and the third was the L98H substitution in cyp51A 476 (position 1784968 on chromosome IV; Supplementary Data 1). Of the significant loci 477 identified on other chromosomes, some mapped to genes involved in secondary 478 metabolism, including fumitremorgin. There were also loci within Afu8g00230, encoding 479 verruculogen synthase, which is associated with A. fumigatus hyphae and conidia modifying 480 the properties of human nasal epithelial cells 59 . A single significant SNP was also identified in 481 Aspf2 (Afu4g09580), a gene which is involved in immune evasion and cell damage 60 . A striking pattern was observed whereby peaks of gene-phenotype associations on 484 Chromosomes I, IV and VII mirrored regions of high FST when comparing Clades A and B 485 (Figure 4b ) likely reflecting the impact of azole selection upon these alleles. Of these 486 regions, 1,385 out of the 2,179 significant loci were located within Chromosome 4. An 487 exception to this was observed in Chromosome VIII, where FST values did not peak above 488 0.370951, but treeWAS p-values were significant. Significant loci within Chromosome VIII 489 are located in genes such as verruculogen synthase, PKS-NRPS synthetase psoA 490 (Afu8g00540) and brevianamide F prenyltransferase (Afu8g00210). Out of the 356 491 significant loci in Chromosome VIII, the majority (n = 354) were located within 500,000 bp of 492 the start of the chromosome, and 62% were intergenic. In order to determine whether there was an observable link between the significant loci 495 identified by treeWAS and azole-resistance, preliminary investigations were undertaken 496 using 28 gene deletion mutants from the COFUN knockout collection in which the 497 corresponding loci were deleted. These mutants were screened for growth on media 498 containing itraconazole relative to the parental control (strain A1160). As expected, null 499 mutant AFUB_063960 (cyp51A) was not able to fully grow in media containing >0.06 mg/L 500 of itraconazole; in addition null mutant AFUB_016810 (abcA) was unable to grow in media 501 containing >0.25 mg/L of itraconazole (Figure 4c ). The control strain and all other null 502 mutants were unable to grow in media containing >1 mg/L (Figure 4c , Table 4 ). Clinical and environmental A. fumigatus consist of genotypes with high relatedness 505 506 We subset our dataset into genotypes from clinical and environmental sources, then applied 507 PCA and DAPC. Both metrics showed a lack of genetic differentiation amongst isolates from 508 clinical and environmental origins showing, importantly, that clinical isolates are drawn from 509 the wider environmental population (Figure 2a type, and did not contain any polymorphisms within cyp51A associated with drug 526 resistance, nor had raised MICs (Table S2) . 527 528 We discovered a further cluster of very highly related A. fumigatus isolates consisting of 14 529 clinical and 14 environmental isolates that all harboured the TR34/L98H cyp51A 530 polymorphism. These isolates were also all MAT1-2 mating type. This clonal clade sits within 531 the larger Clade A and within Cluster 3, and will henceforth be referred to as Clade AA 532 (Figure 1 ). Isolates within Clade AA were found to be broadly distributed across England, 533 Wales, Scotland and the Republic of Ireland (Figure 1b) , covering a spatial distance 534 equivalent to that observed across the whole dataset (Figure 1b fumigatus to the environment, this finding demonstrates that at-risk patients were infected 578 by isolates that have pre-acquired their resistance to azoles in the environment. Phylogenomic analysis confirmed that the population of A. fumigatus was not panmictic, 581 and is structured into a characteristic 'dumbbell' phylogeny marked by two clades with 582 limited inter-clade recombination. We used four hypothesis-free population genetic 583 methods, PCA, DAPC, STRUCTURE and fineStructure to independently confirm the existence 584 of the two clades, as well as the occurrence of strong genetic subclustering within Clade A 585 and evidence of widely occurring clonal genotypes (eg. Clade AA). Azole resistance was 586 defined both genetically, by the occurrence of known resistance alleles, as well as 587 phenotypically using MICs and mapped onto the phylogenetic structure. This analysis 588 showed that Clade A contained the majority of isolates (88%) harbouring polymorphisms in 589 cyp51A associated with drug resistance compared to Clade B, which was predominantly 590 wildtype for cyp51A. Phenotypically-defined resistance recovered a similar pattern with 78% 591 of itraconazole MICs above clinical breakpoints being compartmentalised into Clade A. 592 Further analysis using PCA, DAPC and STRUCTURE showed Clade A is divided into two 593 subclusters, Clusters 1 and 3. All TR34/L98H polymorphisms were found within Cluster 3 594 while Cluster 1 contained isolates with a variety of cyp51A polymorphisms. Interestingly, 595 isolates containing the TR46/Y121F/T289A polymorphism were found in both Clade B and 596 Clade A Cluster 1, but not Clade A Cluster 3. Similarly, the novel polymorphisms 597 TR34/L98H/T289A/I364V/G448S and the unlinked TR34 were found only in Clade A Cluster 3. 598 These analyses suggest that TR-associated azole resistance has evolved a limited number of 599 times and recombination has not yet had the impact of homogenising these alleles across 600 the wider A. fumigatus phylogeny. Similar conclusions were drawn by Camps et al. based on 601 microsatallite and CSP marker analysis of European isolates, who also suggested that the TR-602 resistance form had developed from a common ancestor or restricted set of genetically 603 related isolates 24 . However, the allocation of these novel polymorphisms could also be due 604 to not sampling the entire ecological space available. Future work on global collections of A. 605 fumigatus that have been collected across longer periods of time than in the current study 606 will however be needed to trace and date the spatiotemporal origins of these alleles. 607 608 Our dataset revealed new insights into the emerging complexity of cyp51A-encoded 609 resistance polymorphism. By characterising the genotypes of cyp51A for all isolates we 610 identified a novel cyp51A polymorphism TR34/L98H/T289A/I364V/G448S in four clinical 611 isolates, which appears to be the result of recombination between genotypes containing the 612 It also suggests that either de-linkage from the L98H amino acid substitution occurs through 625 recombination (in this case with the Clade B genetic background) or that parallel origin of 626 the tandem repeat can occur through chance processes. While 86% of resistance to 627 itraconazole defined using MICs was associated with known resistance alleles, we observed 628 12 cases where isolates were resistant to itraconazole yet without any known cyp51A 629 polymorphisms associated with drug resistance (Table 3) . Six of these isolates were also 630 resistant to voriconazole and posaconazole, with two additional isolates displaying 631 resistance to voriconazole and posaconazole only ( appears that the effects of fungicide selection upon the genetic background that these 672 resistance alleles are found, combined with low rates of recombination, is driving much of 673 the observed population genetic structure. We challenged this observation by using a GWAS approach using the recently-developed 676 microbe-specific tool treeWAS. This method maintains high statistical power while being 677 robust to the confounding effects of clonality, population structure and recombination, 678 which we find in this population of A. fumigatus. We found a striking congruence where 679 significant peaks of gene-phenotype associations on Chromosomes I, IV and VII mirrored 680 regions of high FST when compared to Clades A and B (Figure 5a ). This finding therefore links 681 the phenotypes that we have measured (itraconazole breakpoints) to the regions of the 682 genome that are under selection (chromosome IV cyp51A and other regions) and to the 683 genetic structure that we observe (islands of divergence between Clade A and B containing 684 significance treeWAS subsequent scores). Accordingly, it appears that fungicide-associated 685 resistance is driving the patterns of evolution and is the most likely explanation for much of 686 the observed genetic architecture. Yet, there remains much to understand about how these genomic regions of divergence and 689 signatures of selection govern azole resistance in chromosomes with no immediately 690 obvious resistance functions. For instance treeWAS also identified significant SNPs in genes 691 involved in secondary metabolism. Recent research has shown that secondary metabolites 692 combat the host immune system and aid growth in the host (human) environment 72 . Our 693 results identified four SNPs in the gene encoding fumitremorgin C monooxygenase 694 (Afu8g00240), which part of the pathway for secondary metabolite fumitremorgin C, a 695 mycotoxin that acts as a potent ABCG2/BCRP inhibitor that reverses multidrug resistance 73 . This pathway has also been suggested as regulating the brevianamide F gene cluster 74 ; two 697 non-synonymous SNPs in the gene encoding brevianamide F prenyltransferase 698 (Afu8g00210) were also identified as significant in our treeWAS analysis. Further complexity 699 is observed in Chromosome VIII, where FST values did not peak above 0.370951, but 700 treeWAS p-values were highly significant. Significant loci within Chromosome VIII are 701 located in genes such as verruculogen synthase, PKS-NRPS synthetase psoA (Afu8g00540) 702 and brevianamide F prenyltransferase (Afu8g00210). Out of the 356 significant loci in 703 Chromosome VIII, the majority (n = 354) were located within 500,000 bp of the start of the 704 chromosome, and 62% were intergenic. Relative growth of cyp51A and abcA null 705 mutants were effected even at >0.06 mg/L and >0.25 mg/L respectively showing that these 706 two genes have a key role in azole resistance and directly confirming the utility of treeWAS 707 to identify loci associated with itraconazole resistance. Future work now needs to widen our 708 search and to focus on the use of reverse functional genomic approaches to interrogate the 709 function of these genes within the context of their potentially epistatic inter-relationships 710 with the canonical ergosterol biosynthesis cyp51A azole-resistance alleles on Chromosome 711 IV. The ability of fungal pathogens to dispense with sex and to reproduce clonally through 714 mitosis is an important biological feature that enables genotypes of high fitness to rapidly 715 colonise new environments 75 are genetically depauperate not only shows the impact of the genetic sweep that has 725 accompanied the selection of these beneficial mutations, but also suggests that these 726 isolates are highly fit in both clinical and environmental settings. These data indirectly 727 corroborate previous findings that there are no obvious costs associated with the TR-related 728 polymorphisms that might impact the virulence of these isolates 78,79 . Importantly, genetic similarity of paired isolates recovered from environment and clinical 731 sources shows that acquisition of both wildtype and azole-resistant A. fumigatus has 732 occurred widely across this dataset. The statistically significant association between the 733 azole resistant isolates C354, C355 and C357, two clinical isolates and an environmental 734 isolate respectively, isolated within the same city, coupled with their very high genetic 735 similarity suggests an environment-to-patient acquisition of azole resistant A. fumigatus 736 with very high confidence. The low number of SNPs separating the isolates, coupled with 737 nucleotide diversity tests showed that these isolates are genealogically tightly linked, and 738 were strongly supported phylogenetically with 100% bootstrap support also. This shared 739 identity could not have occurred by chance alone, as this shared identity was found to be 740 statistically significant (p < 3.0473 e-252 ). Our PCA analysis showed that clinical isolates are 741 drawn from a wider environmental diversity, with a lack of genetic differentiation amongst 742 isolates in these populations (Figure 2a) . The presence of other significant shared identity 743 between clinical and environmental isolates (Table S5) demonstrates that this 744 environmental to clinical acquisition via inhalation of fungal spores is not a rare occurrence. Our study supports the hypothesis that the widespread use of azoles as fungicides in 747 agriculture is coupled to the increasing isolation of azole-resistant A. fumigatus from 748 environmental sources 14 . That these isolates bear hallmark multi-locus genotypes that are 749 indistinguishable to those recovered from patients supports our conclusion that adaptation 750 to fungicides in the environment is leading to acquisition of A. fumigatus bearing azole-751 resistance genotypes 26,80 . Here, we also identify spatially widespread clones of A. fumigatus 752 that are not only resistant to azoles but are also highly represented in both the environment 753 and the clinic, suggesting that that there are few fitness costs associated with this 754 phenotype. Respiratory viruses such as H1N1 influenza and Severe Acute Respiratory 755 Syndrome (SARS) are known to predispose critically-ill patients to secondary mould 756 infections 2 , and early reports suggest that similar infections will be experienced by patients 757 with COVID-19 64 . The growing numbers of susceptible individuals underscores the need for 758 further surveillance, which is acutely needed to more fully understand the risk posed by 759 environmental reservoirs of pathogenic fungi that, through the use of agricultural 760 antifungals, have evolved resistance to first-line clinical azoles. Ch 56, 10-6 (2011 Hidden killers: human fungal infections Invasive aspergillosis in patients admitted to the intensive 842 care unit with severe influenza: a retrospective cohort study COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From 845 Immunology to Treatment Novel immunologic classification of aspergillosis in adult cystic fibrosis Risk assessment on the impact of environmental usage of 849 triazoles on the development and spread of resistance to medical triazoles in Aspergillus 850 species Diagnosis and management of Aspergillus diseases: executive 852 summary of the 2017 ESCMID-ECMM-ERS guideline Worldwide emergence of resistance 855 to antifungal drugs challenges human health and food security First Detection of TR34/L98H and TR46/Y121F/T289A Cyp51 858 Mutations in Aspergillus fumigatus isolates in the United States First itraconazole resistant Aspergillus fumigatus clinical isolate 861 harbouring a G54E substitution in Cyp51Ap in South America Clinical implications 864 of globally emerging azole resistance in Aspergillus fumigatus Frequency and Evolution of Azole Resistance in Aspergillus fumigatus 867 Associated with Treatment Failure Development of Azole Resistance in Aspergillus fumigatus during 869 Azole Therapy Associated with Change in Virulence Possible Environmental Origin of Resistance of Aspergillus fumigatus to 871 The one health problem of azole resistance in Aspergillus fumigatus: 873 current insights and future research agenda Multiple-Triazole-Resistant Aspergillosis Environmental isolates of azole-resistant Aspergillus fumigatus in 979 Statistical method for testing the neutral mutation hypothesis by DNA 981 polymorphism Verruculogen associated with Aspergillus fumigatus hyphae and 983 conidia modifies the electrophysiological properties of human nasal epithelial cells Aspf2 From Aspergillus fumigatus Recruits Human Immune Regulators 986 for Immune Evasion and Cell Damage Within-host nucleotide diversity of virus populations: 988 Insights from next-generation sequencing Whole-genome sequencing to delineate Mycobacterium tuberculosis 990 outbreaks: a retrospective observational study Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in 993 the Netherlands Confronting and mitigating the risk of COVID-19 associated 995 pulmonary aspergillosis Discovery of a hapE Mutation That Causes Azole Resistance in 997 Aspergillus fumigatus through Whole Genome Sequencing and Sexual Crossing Azole resistance in 1000 Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Evidence for 1003 genetic differentiation and variable recombination rates among Dutch populations of the 1004 opportunistic human pathogen Aspergillus fumigatus A genome-wide scan for diversifying selection signatures in selected 1008 horse breeds Population genomics: how bacterial species form and why they don't 1010 exist A genome-scan method to identify selected loci appropriate for 1012 both dominant and codominant markers: a Bayesian perspective A call to arms: Mustering secondary metabolites for success and 1015 survival of an opportunistic pathogen Differential 1017 inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin 1018 C The Fumitremorgin Gene Cluster of 1020 Aspergillus fumigatus: Identification of a Gene Encoding Brevianamide F Synthetase THE EVOLUTION OF ASEXUAL FUNGI: Reproduction, 1023 Speciation and Classification Bat White-Nose Syndrome: An Emerging Fungal Pathogen? Same-sex mating and the origin of the Vancouver Island Cryptococcus 1027 gattii outbreak In-host adaptation and acquired triazole resistance in Aspergillus 1029 fumigatus: a dilemma for clinical management. The Lancet infectious diseases 16 Triazole fungicides and the 1032 selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus Aspergillus fumigatus: a side-effect of environmental fungicide use? Clinical and environmental isolates of A. fumigatus used in this study, and details of whole-1045 genome alignments COPD = chronic obstructive 1048 pulmonary disease RLL = right lower lobe ABPA = allergic bronchopulmonary aspergillosis. 1049 IV 0 Genes found within regions of high FST in Chromosome 1 when performing fixation index 1066 analysis between Clades A and B in non-overlapping windows of 10 kb 1067 Location Product Description Afu1g15000 4,029 Ortholog of A. flavus putative AMP binding domain protein AFLA_084630 Ortholog of A. flavus conserved hypothetical protein ALFA_082490 Ortholog of A. flavus conserved hypothetical protein AFLA_016260 Ortholog of A. flavus putative ABC multidrug transporter AFLA_082400 Ortholog of A. flavus putative transesterase LovD AFLA_063440 Ortholog of A. fumigatus A1163 AFUB_016290 (protein of unknown function) Has domain with predicted role in transmembrane transport 1077 Figure S1: Microreact project screenshot of the dataset 1078 Phylogenetic analysis of all 218 A. fumigatus isolates with bootstrap support over 1082 1000 replicates performed on WGS SNP data to generate maximum-likelihood phylogeny. 1083 Branch lengths represent average number of SNPs